|
(ÁÖ)À¯¿µÁ¦¾à |
[°æ·Â] PVÆÀ ¸ðÁý
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
05.26 |
05.17 |
|
|
(ÁÖ)¹ÙÀ̳ؽº |
ÀÎõ(¼Ûµµ) PV(ÄɹÌÄ®ÆÄÆ®) °æ·Â»ç¿ø ¸ðÁý
ÀÎõ ¿¬¼ö±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
1³â¡è |
ä¿ë½Ã |
05.16 |
|
|
Çѱ¹ÇÁ¶óÀÓÁ¦¾à |
Á¦¾à°³¹ßºÎ PVÆÀ ½ÅÀÔ ¹× °æ·ÂÁ÷ ä¿ë
¼¿ï ¿µµîÆ÷±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
03.26 |
|
|
Çö´ë¾àÇ°ÁÖ½Äȸ»ç |
[Çö´ë¾àÇ°] Medical Writer ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
3³â¡è |
ä¿ë½Ã |
07.20 |
|
|
(ÁÖ)´ë¿õ¹ÙÀÌ¿À |
Á¦¾à»ç °³¹ßÆÀ PV ´ã´çÀÚ ½ÅÀÔ/°æ·Â ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
07.20 |
|
|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
[LSK global PS] SP / ERA / PL ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
1³â¡è |
ä¿ë½Ã |
12.02 |
|
|
(ÁÖ)ÈÞÁ© |
[PVÆÀ] PV °æ·Â
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
11.10 |
|
|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
[LSK global PS] ERºÎ¼ ÆÀÀå/ ERA °æ·Â/ PL/ A.PL ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
11.01 |
|
|
(ÁÖ)Å¥¶óƼ½º |
ÀÓ»óÀÎÇã°¡ÆÀ PV Á¤±ÔÁ÷ ¸ðÁý
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
06.22 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] Pharmacovigilance Team ÀÎÅÏ»ç¿ø ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
07.02 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] Pharmacovigilance Team ÀÎÅÏ»ç¿ø ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
06.07 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] PV Associate ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
04.23 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] PV ÀÎÅÏ»ç¿ø ¸ðÁý
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.02 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
PV Specialist ¸ðÁý(½ÅÀÔÁö¿ø°¡´É/1³â°è¾à±Ù¹«)
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
02.16 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] PV Associate ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
01.29 |
|